Meet the One Lambda Brand: Delivering Personalized Transplant Care Through Precision

For over 25 years, One Lambda brand assays have been the gold standard for the detection of donor-specific antibodies. As the trusted partner of HLA labs around the world, we provide essential assays to deliver reliable and actionable data for the screening and monitoring of transplant patients. In this short video, discover how we are working to help deliver personalized care to every transplant patient.

One Lambda is dedicated to enabling more personalized treatment in the transplant clinic in order to help our customers improve the lives of patients around the world.

Our comprehensive product portfolio includes a broad range of Antibody Detection assays, HLA Typing products, and post-transplant monitoring solutions, including MMDx® Heart and MMDx® Kidney that are biopsy-based Laboratory Developed Tests that measure gene expression profiling and provide risk assessment for rejection and injury in transplant organs.

The MMDx Heart & Kidney tests can help stratify the risk for conditions like T-cell mediated rejection (TCMR), antibody-mediated rejection (ABMR), acute and chronic injury, atrophy fibrosis, and arterial hyalinosis.

On-Demand Symposia & Webinars

Molecular Assessment of Rejection in Pediatric Heart Transplantation: A Complement to Histopathology


Heather Manion, MSN, RN, CCTC

Heather Manion, MSN, RN, CCTC

Medical Science Liaison

Thermo Fisher Scientific


Defne Magnetta, MD

Defne Magnetta, MD

Pediatric Cardiologist

Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois, USA

Nicoleta Arva, MD, PhD

Nicoleta Arva, MD, PhD

Pediatric Pathologist

Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois, USA

Please join Dr. Defne Magnetta and Dr. Nicole Arva at an upcoming webinar which will review the ISHLT grading system for acute rejection in pediatric heart transplantation, the strengths and pitfalls of histopathology, and how the MMDx™ Heart test can help provide a more comprehensive and accurate diagnosis by combining the power of traditional histopathology with molecular techniques to identify specific genetic and molecular changes associated with diseases.

During this webinar, we’ll discuss how MMDx Heart can provide valuable information in cases of severe cellular rejection following an organ transplant, helping to manage antibody-mediated rejection (ABMR), guide treatment decisions, and improve patient outcomes.

Learning Objectives:

  • To review the ISHLT grading system for acute rejection in pediatric heart transplantation and discuss the strengths and pitfalls of histopathology
  • To discuss the additional information gained from MMDx in cases of severe cellular rejection
  • To illustrate the way in which MMDx and histopathology utilized together may help guide management of AMR

View Webinar

Webinar October 2022
Value of MMDx in Diagnostic Uncertainty in Patients with Heart Transplantation: A Case-Based Presentation

Guest Speaker:
Ashrith Guha, MD, MPH, FACC
Houston Methodist Hospital | Houston, TX

Heart transplant patients often have scenarios where in the clinical presentation and pathological diagnosis on biopsy are discrepant. We will explore the utility of MMDx ® Heart in such patients through a case-based discussion. This webinar will identify the types of scenarios where gene expression profiling is useful for assessing risk of injury or rejection and will discuss the clinical application in follow-up testing.

Learning Objectives:

  • Identify Scenarios where in MMDx Heart could be useful
  • Introduction to diagnostic reporting of MMDx Heart and their interpretation as relevant to clinical presentation
  • Utility of follow up testing in MMDx Heart

View Webinar

ATC 2022
How Emerging Technologies Are Filling The Gaps And Positively Impacting Post-Transplant Care

Once again, the American Transplant Congress delivered an excellent program for all attendees, and we are pleased to have played a part in its success. A highlight for us was our symposium, “How Emerging Technologies are Filling the Gaps and Positively Impacting Post-Transplant Care.” During the presentation, Dr. Rajeev Sharma and Dr. Jamil Azzi discussed how new molecular solutions can provide clinical utility and enhance the patient experience. Additionally, our patient advocate, Valen Keefer, provided a unique perspective to consider. If you missed the live presentation, you can view a recording of this talk and others on our Learning Center!

Guest Speakers:

Jamil R. Azzi, MD
Medical Director, Vascularized Composite Allotransplantation
Associate Director, Kidney and Pancreas Transplantation
Associate Professor
Harvard Medical School

Rajeev Sharma, MD, FACS
Transplant Surgeon
Wayne Health
The Michael and Marian Ilitch Department of Surgery

View Webinar

Webinar May 2022
Using Molecular Diagnostics for Kidney Transplants: Getting There!

Gaurav Gupta
Medical Director of the Kidney Transplant Program | Virginia Commonwealth University

This presentation focused on the use of gene expression profiling for the management of kidney transplant biopsies.

Learning Objectives:

  • Recognize the significance of molecular diagnostic methods in kidney transplantation
  • Understand the complementary diagnostic value of gene expression in kidney transplant biopsies in addition to traditional histology
  • Understand how to incorporate the molecular microscope results into a management plan

View Webinar

ISHLT 2021
Innovations in Rejection Surveillance after Heart Transplantation

Dr. Christopher Lawrence, BSc MBBS LLM MD(Res) MRCP(nephrology) FRCP
Director of Medical Affairs | Thermo Fisher Scientific

Guest Speaker:
Jon A. Kobashigawa, MD │ Director, Heart Transplant Program │Cedars-Sinai Medical Center, Los Angeles, California

For post-transplant management in heart patients, the endomyocardial biopsy is considered the gold standard to detect acute rejection. However, research has found that in biopsy assessments for rejection, concordance among expert pathologists is less than 67%. This presentation will explore case studies and the clinical use of novel technologies, including molecular diagnostic testing of intragraft mRNA transcripts and donor-derived cell-free DNA, for more accurate diagnosis of cellular and antibody-mediated rejection, acute rejection, and cardiac allograft vasculopathy (CAV).

View Webinar

Featured Publication

Restoring Perspective on SOT Biopsy Testing and Analysis

MMDx® Kidney has demonstrated it can reduce subjective interpretation by analyzing over a thousand genes that are variably affected by the specific disease processes and then applying machine-based learning to interpret these results. Read what our Thermo Fisher team had to say in our latest publication summary on the utility of MMDx Kidney, its benefits in early diagnosis of rejection and its subsequent health and economic impact.

Featured Brochure

MMDx Kidney, Heart & Lung

Personalized Transplant Care Through Precision Medicine

Case Study

A Challenging Diagnosis in Kidney Transplantation: A case study on how the Molecular Microscope Diagnostic System for Kidney (MMDx Kidney) provides added confidence and alters management

Dr. Raghavan’s case study at 2021 ATC describes how MMDx Kidney can help in challenging kidney transplant diagnostics, how MMD Kidney reports were more consistent with the patient’s clinical course, and how they increased confidence in the patient management. We bring the full video case study as well as the written summary.

Read the full case study titled "A Challenging Diagnosis in Kidney Transplantation: A case study on how the Molecular Microscope provides added confidence and alters management" at:

Featured Publication

New Research: Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection

In this paper, Dr. Rania El Fekih et al. describe the discovery and validation of two urinary exosomal mRNA multigene signatures for the non-invasive diagnosis of acute TCMR and ABMR as well as chronic active ABMR in kidney transplant patients. The study determined that these exosomes show high stability, suggesting this may be a reliable and non-invasive method for allograft rejection monitoring.

Read the full publication at:

Publication Summary

1 2 3 4 5 6 7


Please provide some basic information to access this content.